# lcsm
Mashup Score:12
my.iaslc.orgIASLC Lightning Member Portal - 1 week
Mashup Score:12
Loading×Sorry to interruptCSS...
-
Join us in 2 weeks at #SCLC23! A meeting focused on preclinical/clinical advances in #SCLC research, including basic research on oncogenesis & biology of disease, preclinical therapeutic research & highlights of ongoing clinical translation. Register https://t.co/bn7tcPelLA #LCSM https://t.co/bn7tcPelLA - view on twitter
Mashup Score:11
IASLCTexas Lung Cancer Conference | IASLC - 7 days
Mashup Score:11
We are excited to invite you to join us at the 1st Annual Texas Lung Cancer Conference in Austin, TX at the historic Austin...
-
Next week join the 1st Annual #TexasLung23 in Austin, TX @ the historic Austin City Limits. This 2-day CME-event will review the latest advances in #lungcancer focused on what a medical oncologist needs to know to provide state–of–the art care today. https://t.co/9ggoUVnvnP #LCSM https://t.co/9ggoUVnvnP - view on twitter
Mashup Score:11
LUNGSTRONG 2018LUNGSTONG | 5k Run - 2 days
Mashup Score:11
Each year hundreds of runners and walkers come out in support of lung cancer research at this family-friendly event. 100% of race proceeds benefit...
-
Let's do this ‼️💪 🏃🏃♂️🏃♀️ #lungcancer #CancerResearch #LCSM @LUNGSTRONGorg @MGHCancerCenter @MGHThoracicOnc @JustinGainor https://t.co/PyUIR3cGXx - view on twitter
Mashup Score:11
ILCN.org (ILCN/WCLC)New Texas Lung Cancer Conference Planned with Busy Clinicians in Mind – ILCN.org (ILCN/WCLC) - 3 days
Mashup Score:11
Stephen Liu, MD, and Tina Cascone, MD, PhD, share what attendees can expect at the first ever Texas Lung Cancer Conference, an upcoming two-day...
-
The upcoming @TLCconference is a new IASLC-endorsed CME meeting tailored to busy clinicians. Drs. @StephenVLiu and Tina Cascone preview the program in #ILCN: https://t.co/WL8ErivGwf #TexasLung23 #LCSM - view on twitter
Mashup Score:11
JTO Clinical and Research ReportsDurvalumab maintenance therapy following definitive concurrent chemoradiotherapy (CRT) is the standard treatment modality for stage III non-small cell lung cancer (NSCLC). Although severe treatment-related...
-
Recovery from treatment-related lymphopenia (TRL) after chemoRT/on durva affects stage III NSCLC outcomes @JTOonline: - 151pts, 27% TRL recovery, 73% not - mPFS 21.9m v NR (p=0.018) favoring TRL grp - ⬆️pre-CRT ALC & TRL assoc w ⬆️PFS @Oncoalert #LCSM https://t.co/QBIJXPRz1D - view on twitter
Mashup Score:10
IASLCTargeted Therapies – Consolidated Radiation | IASLC - 1 week
Mashup Score:10
In this episode of Lung Cancer Considered, recorded at the 2023 Targeted Therapies of Lung Cancer meeting, host Dr. Narjust Florez moderates a conversation...
-
In this episode, recorded at #TTLC23, @NarjustFlorezMD moderates a conversation about the use of consolidated radiation in early-stage #SCLC. Joining the debate are Dr. Lawrence Einhorn (@IUMedSchool) & Dr. Charles Simone (@MSKCancerCenter). Listen: https://t.co/ft0qWTCeuy #LCSM https://t.co/ft0qWTCeuy - view on twitter
ClinicalTrials.gov Identifiers: NCT02367781, NCT02657434, and...
-
Longer #survival in patients with non-small cell #lungcancer with vs without mild to moderate Immune-Related Adverse Events with atezolizumab #immunotherapy Would be good to know if regardless treatment discontinuation #LCSM @OncoAlert @OncoViews https://t.co/74xgByK02r https://t.co/74xgByK02r - view on twitter
Mashup Score:8
JTO Clinical and Research ReportsParticipation in lung cancer screening (LCS) is lower in populations with the highest burden of lung cancer risk (through the social patterning of smoking...
-
Interventions Designed to Increase the Uptake of Lung Cancer Screening: An Equity-Oriented Scoping Review @oncologynursing @ASCO #oncoalert #LCSM https://t.co/BaQyZT7Txz - view on twitter
Mashup Score:7
iaslc.secure-platform.comIASLC – STARS Scholar - 4 days
Mashup Score:7
ALL INTERESTED PATIENT ADVOCATES: Please join us March 28 @ 10 AM MDT for a Zoom session where Janet Freeman-Daily (IASLC STARS Staff Consultant),...
-
Deadline Approaching! Apply by 4/2 for the STARS Scholars Program! A new opportunity for PRAs who want to attend #WCLC23 in person & have demonstrated active participation in PR advocacy activities. Learn more about the STARS Scholar program & Apply: https://t.co/DCVYfRwPD4 #LCSM https://t.co/DCVYfRwPD4 - view on twitter
Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2) alterations are found in approximately 2-5% of non-small cell lung cancers (NSCLCs); the majority are...
Poziotinib in Treatment-Naïve HER2 Ex 20 Mutations: ZENITH20-4- Ph2 @JTOonline - N=80 - ORR 39%; DCR 73%; mPFS 5.6m - TRAEs: rash 45% stomatitis, diarrhea 15% - ⬆️ORR 71% in G778_P780dupGS ➡️ FDA declined 2nd line approval in 2022 pending more data #lcsm https://t.co/6CuMFdBTPk - view on twitter